Arash Jalil, DPM | |
18055 Ventura Blvd, Encino, CA 91316-3517 | |
(818) 261-2900 | |
Not Available |
Full Name | Arash Jalil |
---|---|
Gender | Male |
Speciality | Podiatry |
Experience | 6 Years |
Location | 18055 Ventura Blvd, Encino, California |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1326686015 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
213ES0103X | Podiatrist - Foot & Ankle Surgery | SC006992 (Pennsylvania) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Centinela Hospital Medical Center | Inglewood, CA | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Ashkan Soleymani, Dpm, Inc | 2668484981 | 4 |
News Archive
A new study by researchers from the Automotive Safety Program at Riley Hospital for Children and Indiana University School of Medicine published online July 13, 2009 in the journal Pediatrics reports that the parents of children with special health care needs are doing a good job with the selection of the appropriate child car seat but still need help in using it correctly.
Studies Suggest that ErbB4 Receptor Activation May Be a Novel Therapeutic Avenue for Intestinal Diseases Involving Epithelial Cell Death, According to Research Published in The American Journal of Pathology
Affymax, Inc. today announced that it has received a $5 million development milestone payment from Takeda Pharmaceutical Company as part of the companies' exclusive global agreement to develop and commercialize Hematide™, Affymax's investigational drug for the treatment of anemia in chronic renal failure patients. The milestone was achieved with the initiation of Phase 3 clinical testing of Hematide to treat anemia in chronic renal failure patients in Japan.
Smoking cigarettes is a significant risk factor for developing rheumatoid arthritis and may have a negative impact on the effectiveness of anti-tumour necrosis factor inhibitors in RA patients taking these treatments, according to results of two studies presented today at EULAR 2010, the Annual Congress of the European League Against Rheumatism in Rome, Italy.
Angiotech Pharmaceuticals, today announced that its Board of Directors has authorized the Company and certain of its subsidiaries to voluntarily file under the Companies' Creditors Arrangement Act in order to continue implementation of its previously announced recapitalization transaction.
› Verified 2 days ago
Provider Name | Ashkan Soleymani, Dpm, Inc |
---|---|
Provider Type | Part B Supplier - Clinic/group Practice |
Provider Identifiers | NPI Number: 1043252513 PECOS PAC ID: 2668484981 Enrollment ID: O20060630000296 |
News Archive
A new study by researchers from the Automotive Safety Program at Riley Hospital for Children and Indiana University School of Medicine published online July 13, 2009 in the journal Pediatrics reports that the parents of children with special health care needs are doing a good job with the selection of the appropriate child car seat but still need help in using it correctly.
Studies Suggest that ErbB4 Receptor Activation May Be a Novel Therapeutic Avenue for Intestinal Diseases Involving Epithelial Cell Death, According to Research Published in The American Journal of Pathology
Affymax, Inc. today announced that it has received a $5 million development milestone payment from Takeda Pharmaceutical Company as part of the companies' exclusive global agreement to develop and commercialize Hematide™, Affymax's investigational drug for the treatment of anemia in chronic renal failure patients. The milestone was achieved with the initiation of Phase 3 clinical testing of Hematide to treat anemia in chronic renal failure patients in Japan.
Smoking cigarettes is a significant risk factor for developing rheumatoid arthritis and may have a negative impact on the effectiveness of anti-tumour necrosis factor inhibitors in RA patients taking these treatments, according to results of two studies presented today at EULAR 2010, the Annual Congress of the European League Against Rheumatism in Rome, Italy.
Angiotech Pharmaceuticals, today announced that its Board of Directors has authorized the Company and certain of its subsidiaries to voluntarily file under the Companies' Creditors Arrangement Act in order to continue implementation of its previously announced recapitalization transaction.
› Verified 2 days ago
Provider Name | Home Foot Care Inc |
---|---|
Provider Type | Part B Supplier - Clinic/group Practice |
Provider Identifiers | NPI Number: 1447480785 PECOS PAC ID: 4981744257 Enrollment ID: O20091217000066 |
News Archive
A new study by researchers from the Automotive Safety Program at Riley Hospital for Children and Indiana University School of Medicine published online July 13, 2009 in the journal Pediatrics reports that the parents of children with special health care needs are doing a good job with the selection of the appropriate child car seat but still need help in using it correctly.
Studies Suggest that ErbB4 Receptor Activation May Be a Novel Therapeutic Avenue for Intestinal Diseases Involving Epithelial Cell Death, According to Research Published in The American Journal of Pathology
Affymax, Inc. today announced that it has received a $5 million development milestone payment from Takeda Pharmaceutical Company as part of the companies' exclusive global agreement to develop and commercialize Hematide™, Affymax's investigational drug for the treatment of anemia in chronic renal failure patients. The milestone was achieved with the initiation of Phase 3 clinical testing of Hematide to treat anemia in chronic renal failure patients in Japan.
Smoking cigarettes is a significant risk factor for developing rheumatoid arthritis and may have a negative impact on the effectiveness of anti-tumour necrosis factor inhibitors in RA patients taking these treatments, according to results of two studies presented today at EULAR 2010, the Annual Congress of the European League Against Rheumatism in Rome, Italy.
Angiotech Pharmaceuticals, today announced that its Board of Directors has authorized the Company and certain of its subsidiaries to voluntarily file under the Companies' Creditors Arrangement Act in order to continue implementation of its previously announced recapitalization transaction.
› Verified 2 days ago
Mailing Address | Practice Location Address |
---|---|
Arash Jalil, DPM 4942 Newcastle Ave, Encino, CA 91316-4209 Ph: (818) 261-2900 | Arash Jalil, DPM 18055 Ventura Blvd, Encino, CA 91316-3517 Ph: (818) 261-2900 |
News Archive
A new study by researchers from the Automotive Safety Program at Riley Hospital for Children and Indiana University School of Medicine published online July 13, 2009 in the journal Pediatrics reports that the parents of children with special health care needs are doing a good job with the selection of the appropriate child car seat but still need help in using it correctly.
Studies Suggest that ErbB4 Receptor Activation May Be a Novel Therapeutic Avenue for Intestinal Diseases Involving Epithelial Cell Death, According to Research Published in The American Journal of Pathology
Affymax, Inc. today announced that it has received a $5 million development milestone payment from Takeda Pharmaceutical Company as part of the companies' exclusive global agreement to develop and commercialize Hematide™, Affymax's investigational drug for the treatment of anemia in chronic renal failure patients. The milestone was achieved with the initiation of Phase 3 clinical testing of Hematide to treat anemia in chronic renal failure patients in Japan.
Smoking cigarettes is a significant risk factor for developing rheumatoid arthritis and may have a negative impact on the effectiveness of anti-tumour necrosis factor inhibitors in RA patients taking these treatments, according to results of two studies presented today at EULAR 2010, the Annual Congress of the European League Against Rheumatism in Rome, Italy.
Angiotech Pharmaceuticals, today announced that its Board of Directors has authorized the Company and certain of its subsidiaries to voluntarily file under the Companies' Creditors Arrangement Act in order to continue implementation of its previously announced recapitalization transaction.
› Verified 2 days ago
Dawn R. Buratti, D.p.m., Inc Podiatrist Medicare: Medicare Enrolled Practice Location: 5400 Balboa Blvd Ste 325, Encino, CA 91316 Phone: 818-701-6300 Fax: 866-513-4995 | |
Gilman Podiatry, A Prof. Corp Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 17777 Ventura Blvd, Suite 230, Encino, CA 91316 Phone: 818-905-1000 Fax: 818-342-1609 | |
Tower Podiatry-the Foot And Ankle Surgical Institute Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 16661 Ventura Blvd, Suite 705, Encino, CA 91436 Phone: 310-657-2828 Fax: 310-657-9733 | |
Leonora Fihman, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 5400 Balboa Blvd, Encino, CA 91316 Phone: 818-907-6100 | |
Maurice R Masliah Dpm Podiatrist Medicare: Medicare Enrolled Practice Location: 5400 Balboa Blvd Ste 225, Encino, CA 91316 Phone: 818-981-3344 Fax: 818-981-4777 | |
Dr. Majid Seyedin, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 17777 Ventura Blvd, 252, Encino, CA 91316 Phone: 323-912-9220 Fax: 818-221-0534 | |
Leonora Fihman, Dpm, Pc Podiatrist Medicare: Medicare Enrolled Practice Location: 5400 Balboa Blvd, 321, Encino, CA 91316 Phone: 818-907-6110 |